Filing Flows

Filing Flows › Black Diamond Therapeutics (BDTX) › Next earnings date

Black Diamond Therapeutics (BDTX) earnings on Nov 9, 2026: what to expect

Black Diamond Therapeutics (BDTX) is expected to report earnings on Nov 9, 2026 (estimated), today, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.06 (−$0.24 to $0.62, 6 estimates) on revenue of $6.2M, against −$0.15 a year ago. It beat the EPS estimate in 100% of the quarters on record; Filing Flows' model gives it a 84% chance of beating next time.

Report dateNov 9, 2026 (estimated)
Days to go0
EPS estimate−$0.06
Revenue estimate$6.2M
Beat rate100%

The last report

Black Diamond Therapeutics reported revenue of $70.0M for the first quarter 2025, net earnings $56.5M. How it makes money → · Every quarter →

Black Diamond Therapeutics: EPS against the estimate, last 4 reportsBlack Diamond Therapeutics: EPS against the estimate, last 4 reportsEstimateReported−$0.23−$0.15Nov 25−$0.17−$0.14Mar 26−$0.21−$0.16May 26−$0.20−$0.17Aug 26
Latest (Aug 26): Estimate −$0.20, Reported −$0.17.

Black Diamond Therapeutics' latest quarter

Black Diamond Therapeutics, Q1 2025: revenue $70.0M, operating margin 77.9%, net earnings $56.5M, operating cash flow $53.4M. The chart follows the revenue to costs, profit and cash.

Questions

When does BDTX report earnings?

Black Diamond Therapeutics is expected to report on Nov 9, 2026 (estimated).

What are analysts expecting from Black Diamond Therapeutics?

EPS of −$0.06 and revenue of $6.2M for the quarter.

Does Black Diamond Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.